Immunocore Holdings is a UK-based biotechnology company that specializes in developing immunotherapies to treat infectious, cancerous, and autoimmune diseases. The company's therapy, KIMMTRAK, is a treatment option for patients affected by unresectable or metastatic uveal melanoma. Immunocore is also exploring other programs for oncology and infectious diseases, with IMC-C103C and IMC-F106C being a part of the former and IMC-I109V and IMC-M113V under the latter.